PRESS RELEASES<< Back
Chimerix to Present at the 37th Annual J.P. Morgan Healthcare Conference
Dr. Berrey will present a corporate overview with plans and expected milestones for 2019, which will highlight the Company's core focus on progressing both oral, short-course brincidofovir (BCV) and the intravenous (IV) BCV program. Following planned discussions with
Major milestones are also anticipated in 2019 for oral BCV as a medical countermeasure for smallpox. The key rabbitpox study is expected to provide interim data in the first half of 2019, and the second animal model (mousepox) should read out in the second half of the year. Data from these animal model studies, if positive, could support regulatory approvals for BCV for the treatment of smallpox. The procurement of BCV to the Strategic National Stockpile, however, could be achieved prior to a regulatory decision.
The company has previously presented the safety and tolerability data from a Phase 1 study of CMX521, which supported continued development of the first small molecule in clinical development for prophylaxis or treatment of norovirus. Evaluation of active antiviral concentrations in gastrointestinal biopsies indicate that improved intracellular delivery is needed prior to conducting efficacy studies. While the Company’s present focus remains on the oral and IV BCV programs, updates on potential further clinical development activity in the norovirus program will be provided later in 2019 if warranted, including possible strategies for enhanced delivery of CMX521.
A live audio webcast of the presentation will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.
Source: Chimerix, Inc.